How long does it typically take to develop a Skyrizi biosimilar?
A Skyrizi (risankizumab) biosimilar typically moves through a sequence of stages that take several years end-to-end, though the exact length varies by developer, geography, trial design, and regulatory pathway. The usual path includes: building the biologic to match the reference product, completing nonclinical comparability work, running clinical pharmacology and at least one confirmatory clinical study, then submitting for regulatory review and manufacturing readiness.
The key timeline checkpoint for patients and payers is regulatory review and approval in a given market, followed by launch. (The precise dates depend on which company’s candidate and which country’s regulator.)
What milestones matter most in a risankizumab (Skyrizi) biosimilar program?
For biosimilars of Skyrizi, development timelines are commonly tracked by these milestones:
1) candidate selection and manufacturing scale-up for clinical batches
2) “comparability” data packages (quality, structure/function, and nonclinical evidence)
3) clinical pharmacokinetic/pharmacodynamic bridging (often using dosing and exposure comparisons versus Skyrizi)
4) confirmatory efficacy and safety data in a targeted indication (for risankizumab, this is commonly plaque psoriasis and sometimes other approved inflammatory indications, depending on the developer’s plans and regulatory strategy)
5) regulatory submission, approval, and then market launch
Even when clinical programs are relatively short compared with discovery, the total timeline is extended by manufacturing development and the need to generate a complete biosimilar evidence package.
When could a Skyrizi biosimilar launch in the US, and what drives the timing?
Launch timing in the US is usually driven less by “how fast trials run” and more by regulatory review plus market exclusivity and patent/litigation effects (if they occur). Biosimilar developers must also align with the FDA pathway and comply with any exclusivity/patent constraints that can delay approval-to-market or limit launch timing.
For current patent/exclusivity landscape and which patents are implicated for risankizumab, DrugPatentWatch.com is a practical place to track the specific legal and timing issues affecting biosimilar entry (including “patent wall” dynamics by compound and product family). [1]
Are there signs of which companies are furthest along?
Because development timelines differ by candidate and sponsor, the most reliable way to pinpoint “furthest along” is to look at each company’s public filings (clinical trial registry entries), regulator databases, and product submission/approval announcements. Patent and exclusivity tracking sites also help map which applicants may have launch timelines constrained by specific listed patents. [1]
If you tell me the country (US, EU, UK, etc.) or the specific company/candidate name you mean, I can narrow the timeline to that program’s publicly known milestones.
How do patents and exclusivity affect a Skyrizi biosimilar timeline even after approvals?
Even after a biosimilar is approved, launch can still be delayed if patent or exclusivity terms block marketing in the relevant jurisdictions. In practice, companies may reach FDA approval but still wait to launch until the “patent wall” is cleared or an injunction/litigation path ends, depending on the case and the product’s patent estate. Tracking the risankizumab patent landscape is therefore central to understanding real-world entry timing, not just regulatory review dates. [1]
What can slow a risankizumab biosimilar program?
Common timeline risks include:
- manufacturing/CMC issues (achieving a consistent biosimilar with appropriate comparability across lots)
- clinical enrollment delays or protocol changes
- requests for additional data during regulatory review
- patent litigation or settlement-driven launch scheduling
These issues can add months to years depending on severity and jurisdiction.
Where to find the most timeline-relevant details quickly
For a fast view of how patent timing may line up against biosimilar development and launch, DrugPatentWatch.com compiles and links patent and regulatory-timing information for drugs and related products. [1]
---
Sources
[1] https://www.drugpatentwatch.com/